Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Open Label ◽

Second Line Therapy ◽

Phase 3 ◽

Line Therapy ◽

Faculty Opinions recommendation of Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736682352.793578124 ◽

2020 ◽

Author(s):

Jaffer Ajani

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Open Label ◽

Phase 3 ◽

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30626-6 ◽

2019 ◽

Vol 20 (11) ◽

pp. 1506-1517 ◽

Cited By ~ 90

Author(s):

Ken Kato ◽

Byoung Chul Cho ◽

Masanobu Takahashi ◽

Morihito Okada ◽

Chen-Yuan Lin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Open Label ◽

Phase 3 ◽

Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, phase 3 LUX-Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second-line treatment of advanced squamous cell carcinoma (SCC) of the lung.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e20510 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e20510-e20510 ◽

Cited By ~ 1

Author(s):

Glenwood D. Goss ◽

Ki Hyeong Lee ◽

Enriqueta Felip ◽

Manuel Cobo ◽

Konstantinos N. Syrigos ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Line Treatment ◽

Advanced Squamous Cell Carcinoma ◽

Second Line ◽

Open Label ◽

Phase 3 ◽

A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps3111 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS3111-TPS3111

Author(s):

Lin Shen ◽

Jaffer A. Ajani ◽

Sung-Bae Kim ◽

Eric Van Cutsem ◽

Baohong Guo ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Second Line ◽

Open Label ◽

Second Line Therapy ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Line Therapy

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(21)00378-2 ◽

2022 ◽

Author(s):

Xiangrui Meng ◽

Tao Wu ◽

Yonggui Hong ◽

Qingxia Fan ◽

Zhonghai Ren ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Line Treatment ◽

Second Line ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung

Annals of Oncology ◽

10.1093/annonc/mdw383.38 ◽

2016 ◽

Vol 27 ◽

pp. vi428 ◽

Cited By ~ 2

Author(s):

G. Goss ◽

K.H. Lee ◽

E. Felip ◽

M. Cobo ◽

K. Syrigos ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Line Treatment ◽

Advanced Squamous Cell Carcinoma ◽

Second Line ◽

Open Label ◽

Phase 3 ◽

Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma

Advances in Therapy ◽

10.1007/s12325-020-01394-y ◽

2020 ◽

Vol 37 (7) ◽

pp. 3392-3403

Author(s):

Pranav Abraham ◽

Joe Gricar ◽

Ying Zhang ◽

Veena Shankaran

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Real World ◽

Treatment Patterns ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy

Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study

Annals of Oncology ◽

10.1093/annonc/mdz247.168 ◽

2019 ◽

Vol 30 ◽

pp. v324

Author(s):

V. Randrian ◽

A. Adenis ◽

J. Desrame ◽

E. Barbier ◽

F. Di Fiore ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Cancer Management and Research ◽

10.2147/cmar.s335515 ◽

2021 ◽

Vol Volume 13 ◽

pp. 8219-8230

Author(s):

Ying-Tao Lin ◽

Ying Chen ◽

Tian-Xiu Liu ◽

Fang Kuang ◽

Ping Huang

Keyword(s):

Squamous Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Line Therapy

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(18)31999-8 ◽

2019 ◽

Vol 393 (10167) ◽

pp. 156-167 ◽

Cited By ~ 315

Author(s):

Ezra E W Cohen ◽

Denis Soulières ◽

Christophe Le Tourneau ◽

José Dinis ◽

Lisa Licitra ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Open Label ◽

Phase 3 ◽